Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Treason trial of South Sudan's suspended VP is further eroding peace deal, UN experts say - 2Do-It-Yourself Home Style on a Careful spending plan: Imaginative Thoughts and Tasks
- 3Vaccine committee votes to scrap universal hepatitis B shots for newborns despite outcry from children’s health experts
- 4One third of Spanish pork export certificates blocked since swine fever outbreak, minister says
- 5The most effective method to Pick the Right Material Organization: Fundamental Tips
- Netflix is releasing a documentary on Elizabeth Smart. What to know about her kidnapping, rescue and where she is now.
- 5 Great Crossover Vehicles For Eco-friendliness In 2024
- Ski Resorts Universally: A Colder time of year Wonderland Guide
- Figure out how to Use Your Brain research Degree in the Gig Market
- I served on the expert committee that advised the government on new dietary guidelines – most of our recommendations were ignored
- Pilot captures jaw-dropping northern lights show from 36,000 feet (photos)
- Flying without a Real ID? That'll soon cost you $45, TSA says.
- Instructions to Upgrade the Proficiency of Your Sunlight powered chargers
- Which Film Has the Incomparable Melodic Score?
